Bextra Label Changes Under Discussion After Hypersensitivity Reactions
Executive Summary
Pfizer and Pharmacia are in discussions with FDA regarding safety-related label changes for Bextra, Pfizer said during its third quarter earnings call Oct. 16
You may also be interested in...
Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings
Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor
Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings
Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events